Alpine's Pipeline
We have a diverse pipeline of multi-targeted therapies in development for both autoimmune and inflammatory disease.
INFLAMMATORY DISEASES
Povetacicept (ALPN-303)
Dual B Cell Cytokine (BAFF/APRIL) Antagonist

Commmercial Rights:

RUBY-2 study, a placebo-controlled, dose-ranging, randomized phase 2 study in systemic lupus erythematosus (SLE).

Commmercial Rights:

RUBY-3 (NCT05732402) – Phase 1b Glomerulonephritis Basket Study
RUBY-3 is a is a multi-ascending dose, multi-cohort open label study that will enroll subjects with proteinuric IgA nephropathy, lupus nephritis or primary membranous nephropathy in small disease- and dose-specific cohorts for up to 48 weeks. Endpoints will include changes in disease-specific autoantibodies as well as proteinuria, eGFR and various definitions of renal response

Commmercial Rights:

RUBY-4 (NCT05757570)- Phase 1b Autoimmune Cytopenia Basket Study
RUBY-4 is a parallel-arm, multi-cohort open label study that will enroll patients with immune thrombocytopenia, warm autoimmune hemolytic anemia, or cold agglutinin disease in disease-specific cohorts, using a 2-stage Fleming design for up to 48 weeks. Endpoints will include standard definitions of response, such as durable responses. Changes in anti-platelet or anti-red blood cell autoantibodies will also be followed.
Partnered Programs
Acazicolcept (ALPN-101)
Dual CD28/ICOS Antagonist

Partners:

Acazicolcept is a first-in-class dual inhibitor of the CD28 and ICOS T cell costimulatory pathways. The molecule is being developed for treatment of severe inflammatory diseases.
We are currently enrolling Synergy, a phase 2 study of acazicolcept in patients with Systemic Lupus Erythematosus (NCT04835441). This randomized, double-blind, placebo-controlled study was designed to evaluate the safety, tolerability, efficacy, immunogenicity, pharmacokinetics, and pharmacodynamics of acazicolcept.
Discovery Collaboration
Immunology

Next Generation TCR T-cell Therapies

For more information on our ongoing clinical trials please refer to the clinical trials portion of our website. For additional information please refer to our corporate filings, corporate presentations, and scientific publications.